Andrew Davies1, Charlotte Leach2, Ricardo Caponero3, Andrew Dickman4, David Fuchs5, Judith Paice6, Anton Emmanuel7. 1. Royal Surrey County Hospital, Egerton Road, Guildford, GU2 7XX, UK. adavies12@nhs.net. 2. Royal Surrey County Hospital, Egerton Road, Guildford, GU2 7XX, UK. 3. Hospital Alemão Oswaldo Cruz, São Paulo, Brazil. 4. Royal Liverpool Hospital, Liverpool, UK. 5. Kepler University Hospital, Linz, Austria. 6. Northwestern University, Chicago, IL, USA. 7. University College London Hospitals, London, UK.
Abstract
PURPOSE: The Palliative Care Study Group of the Multinational Association for Supportive Care in Cancer formed a subgroup to develop evidence-based recommendations on the management of constipation in patients with advanced cancer. METHODS: These recommendations were developed in accordance with the MASCC Guidelines Policy. A search strategy for Medline was developed, and the Cochrane Database of Systematic Reviews and the Cochrane Central Register of Controlled Trials were explored for relevant reviews/trials respectively. The recommendations were categorised by the level of evidence and a "category of guideline" based on the level of evidence (i.e. "recommendation", "suggestion", or "no guideline possible"). RESULTS: The group produced 15 recommendations, with varying levels of evidence and so varying categories of guideline. The recommendations relate to the assessment, the treatment, and the re-assessment of constipation. CONCLUSIONS: These recommendations provide a framework for the management of constipation in advanced cancer, although every patient needs individualised management.
PURPOSE: The Palliative Care Study Group of the Multinational Association for Supportive Care in Cancer formed a subgroup to develop evidence-based recommendations on the management of constipation in patients with advanced cancer. METHODS: These recommendations were developed in accordance with the MASCC Guidelines Policy. A search strategy for Medline was developed, and the Cochrane Database of Systematic Reviews and the Cochrane Central Register of Controlled Trials were explored for relevant reviews/trials respectively. The recommendations were categorised by the level of evidence and a "category of guideline" based on the level of evidence (i.e. "recommendation", "suggestion", or "no guideline possible"). RESULTS: The group produced 15 recommendations, with varying levels of evidence and so varying categories of guideline. The recommendations relate to the assessment, the treatment, and the re-assessment of constipation. CONCLUSIONS: These recommendations provide a framework for the management of constipation in advanced cancer, although every patient needs individualised management.
Entities:
Keywords:
Constipation; Neoplasms; Palliative care; Practice guideline
Authors: Greger Lindberg; Saeed S Hamid; Peter Malfertheiner; Ole Ostergaard Thomsen; Luis Bustos Fernandez; James Garisch; Alan Thomson; Khean-Lee Goh; Rakesh Tandon; Suliman Fedail; Benjamin C Y Wong; Aamir Ghafoor Khan; Justus H Krabshuis; Anton LeMair Journal: J Clin Gastroenterol Date: 2011-07 Impact factor: 3.062
Authors: M Camilleri; D A Drossman; G Becker; L R Webster; A N Davies; G M Mawe Journal: Neurogastroenterol Motil Date: 2014-08-28 Impact factor: 3.598
Authors: P J Larkin; N P Sykes; C Centeno; J E Ellershaw; F Elsner; B Eugene; J R G Gootjes; M Nabal; A Noguera; C Ripamonti; F Zucco; W W A Zuurmond Journal: Palliat Med Date: 2008-10 Impact factor: 4.762
Authors: Ana Fernández-Montes; Guillermo de Velasco; Santiago Aguín; Cristina Farriols; María Guirado-Risueño; Vanessa G Jerviz-Guía; María Victoria Baeza-Nadal; Rodolfo Chicas-Sett; José Luis Fírvida; Francisco García-Navalón; Patricia Martín; Carmen Perezagua-Marín; Dulce Rodríguez; Joan Santamaría; Tamara Saurí; Manuel Cobo Journal: Curr Treat Options Oncol Date: 2021-02-26
Authors: Chung-Wah Cheng; Hoi-Fung Mok; Cora W S Yau; Jasmine T M Chan; Yu-Chen Kang; Pui-Yan Lam; Linda L D Zhong; Chen Zhao; Bacon F L Ng; Annie O L Kwok; Doris M W Tse; Zhao-Xiang Bian Journal: Chin Med Date: 2022-03-02 Impact factor: 5.455